

Ref no: 099250820
From: Commercial
Date: 25/08/20
Subject: Bacterial and fungal infections

REQUEST & RESPONSE

I am researching the treatment of bacterial and fungal infections in the UK secondary care sector. Could you please answer the following three questions

Q1. How many patients has your Trust treated (for any indication) in the last 12 months with the following drugs:

- Piperacillin/tazobactam - **(0)**
- Ceftazidime/avibactam (Zavicefta) ***<5**
- Ceftolozane/tazobactam (Zerbaxa) **Never used**
- Meropenem/ vaborbactam (Vaborem) **Never used**
- Cefiderocol (Fetcroja) **Never used**
- Carbapenems – Meropenem(123), Imipenem(0)/cilastatin(0), Ertapenem(78) – **total 201**
- Aminoglycosides – Gentamicin(70), Amikacin(***<5**), Tobramycin(9), Neomycin(1), Streptomycin (0), **Total - 85**
- Cephalosporins – Cefotaxime(0), Ceftazidime(10), Ceftriaxone(2), Cefadroxil(0), Cefalexin(862), Cefaclor(64), Cefoxitin(0), Cefuroxime(67), Cefixime(0), **Total - 1005**
- Quinolones - Ciprofloxacin(837), Levofloxacin(306), Ofloxacin(110), Moxifloxacin(35) – **Total - 1289**
- Polymixins (such as: Colistin) – **injection 8 patients, nebs 36 patients (some patients multiple issues)**
- Amphotericin B/amphotericin liposomal (AmBisome) – **(0)**

- Isavuconazole (Cresemba) **oral preparation * <5**

- Posaconazole (Noxafil) **Po capsules * <5**

Q2. How many patients has your Trust treated in the last 12 months for:

- Complicated Intra Abdominal Infections (cIAI)
- Complicated Urinary tract infections (cUTI)
- Hospital Acquired Pneumonia (HAP) and/or Ventilator Associated Pneumonia (VAP)
- Mucormycosis

	September 19 to August 20
Urinary Tract Infection	2767
Hospital acquired pneumonia	487
Intra Abdominal sepsis	6
Murcomycosis	0

Q3. For patients treated with Ceftazidime/avibactam (Zavicefta) in the last 12 months, can you please provide the number of patients suffering from:

- Complicated Intra Abdominal Infections (cIAI) **0 patients**
- Complicated Urinary Tract infections (cUTI) **0 patients**
- Hospital Acquired Pneumonia (HAP) and/or Ventilator Associated Pneumonia (VAP) **0 patients**
- Gram-Negative bacterial infections – *** <5**

*** Please note:** We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection

principle. This states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.